Literature DB >> 30839115

Metabolism-induced tumor activator 1 (MITA1), an Energy Stress-Inducible Long Noncoding RNA, Promotes Hepatocellular Carcinoma Metastasis.

Meilin Ma1, Haixia Xu1, Geng Liu1, Jing Wu1, Chunhua Li1, Xiuxuan Wang1, Sifan Zhang1, Heng Xu2, Shenggen Ju3, Wei Cheng2, Lunzhi Dai2, Yuquan Wei2, Yan Tian1, Xianghui Fu1.   

Abstract

Metastasis is the main cause of cancer-related death, yet the underlying mechanisms are still poorly understood. Long noncoding RNAs (lncRNAs) are emerging as crucial regulators of malignancies; however, their functions in tumor metastasis remain largely unexplored. In this study, we identify a lncRNA, termed metabolism-induced tumor activator 1 (MITA1), which is up-regulated in hepatocellular carcinoma (HCC) and contributes to metastasis. MITA1, a chromatin-enriched lncRNA discovered by our nuclear RNA sequencing, is significantly induced by energy stress. This induction of MITA1 is governed by the liver kinase B1-adenosine monophosphate-activated protein kinase (LKB1-AMPK) pathway and DNA methylation. Knockdown of MITA1 dramatically inhibits the migration and invasion of liver cancer cells in vitro and HCC metastasis in vivo. Mechanistically, MITA1 promotes the epithelial-mesenchymal transition, an early and central step of metastasis, which may partly attribute to an increase in Slug (snail family zinc finger 2) transcription. MITA1 deficiency reduces the expression of the mesenchymal cell markers, especially Slug, whereas Slug overexpression greatly impairs the effects of MITA1 deficiency on HCC migration and invasion. Correspondingly, there is a positive correlation between the levels of MITA1 and Slug precursors in HCC tissues.
Conclusion: Our data reveal MITA1 as a crucial driver of HCC metastasis, and highlight the identified AMPK-MITA1-Slug axis as a potential therapeutic strategy for HCC.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30839115     DOI: 10.1002/hep.30602

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  27 in total

Review 1.  Long non-coding RNA small nucleolar RNA host genes: functions and mechanisms in hepatocellular carcinoma.

Authors:  Yuan Li; Xinxin Wang; Shiyong Chen; Biao Wu; Yu He; Xueqin Du; Xiaojun Yang
Journal:  Mol Biol Rep       Date:  2022-01-06       Impact factor: 2.316

Review 2.  Stressing the Regulatory Role of Long Non-Coding RNA in the Cellular Stress Response during Cancer Progression and Therapy.

Authors:  Yi-Zhen Wu; Yong-Han Su; Ching-Ying Kuo
Journal:  Biomedicines       Date:  2022-05-23

3.  UBE2O promotes lipid metabolic reprogramming and liver cancer progression by mediating HADHA ubiquitination.

Authors:  Meilin Ma; Changhui Zhang; Rong Cao; Dongmei Tang; Xiongbo Sang; Sailan Zou; Xiuxuan Wang; Haixia Xu; Geng Liu; Lunzhi Dai; Yan Tian; Xiang Gao; Xianghui Fu
Journal:  Oncogene       Date:  2022-10-22       Impact factor: 8.756

4.  Energy stress-induced linc01564 activates the serine synthesis pathway and facilitates hepatocellular carcinogenesis.

Authors:  Guang Zhang; Yang Yang; Hao Hu; Kaiyue Liu; Bingyan Li; Yu Zhu; Zhongyu Wang; Qingfa Wu; Yide Mei
Journal:  Oncogene       Date:  2021-03-19       Impact factor: 9.867

Review 5.  The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma.

Authors:  Shunjie Xia; Yu Pan; Yuelong Liang; Junjie Xu; Xiujun Cai
Journal:  EBioMedicine       Date:  2020-01-06       Impact factor: 8.143

Review 6.  Long non-coding RNAs regulate drug resistance in cancer.

Authors:  Kaisheng Liu; Lin Gao; Xiaoshi Ma; Juan-Juan Huang; Juan Chen; Leli Zeng; Charles R Ashby; Chang Zou; Zhe-Sheng Chen
Journal:  Mol Cancer       Date:  2020-03-12       Impact factor: 27.401

Review 7.  The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective.

Authors:  Juan Pablo Unfried; Paloma Sangro; Laura Prats-Mari; Bruno Sangro; Puri Fortes
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

8.  A novel lncRNA PLK4 up-regulated by talazoparib represses hepatocellular carcinoma progression by promoting YAP-mediated cell senescence.

Authors:  Yan Jia; Huanhuan Jin; Liyuan Gao; Xiang Yang; Feixia Wang; Hai Ding; Anping Chen; Shanzhong Tan; Feng Zhang; Jiangjuan Shao; Shijun Wang; Shizhong Zheng
Journal:  J Cell Mol Med       Date:  2020-04-03       Impact factor: 5.310

9.  LINC00978 promotes the progression of hepatocellular carcinoma by regulating EZH2-mediated silencing of p21 and E-cadherin expression.

Authors:  Xueying Xu; Jianmei Gu; Xiaoge Ding; Guohong Ge; Xueyan Zang; Runbi Ji; Meng Shao; Zheying Mao; Yu Zhang; Jiayin Zhang; Fei Mao; Hui Qian; Wenrong Xu; Hui Cai; Feng Wang; Xu Zhang
Journal:  Cell Death Dis       Date:  2019-10-03       Impact factor: 8.469

Review 10.  Recent advances in unraveling the molecular mechanisms and functions of HOXA11‑AS in human cancers and other diseases (Review).

Authors:  Cheng Wei; Liangjuan Zhao; Hao Liang; Yingwei Zhen; Lei Han
Journal:  Oncol Rep       Date:  2020-03-19       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.